- 1 **TITLE:** Longitudinal Profiling of the Intestinal Microbiome in Children with Cystic Fibrosis
- 2 Treated with Elexacaftor-Tezacaftor-Ivacaftor
- 3

4 WORD COUNT (MAIN TEXT): 4733

5

6 **AUTHORS:** Seth A. Reasoner^{1*}, Rachel Bernard^{2*}, Adam Waalkes³, Kelsi Penewit³, Janessa

- 7 Lewis³, Andrew G. Sokolow⁴, Rebekah F. Brown⁴, Kathryn M. Edwards⁵, Stephen J. Salipante³,
- 8 Maria Hadjifrangiskou^{1,6,7}, Maribeth R. Nicholson^{2,7}
- 9

10 **AFFILIATIONS**:

- 1. Division of Molecular Pathogenesis, Department of Pathology, Microbiology & Immunology,
- 12 Vanderbilt University Medical Center, Nashville, TN, USA
- 13 2. Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Monroe
- 14 Carrell Junior Children's Hospital at Vanderbilt, Nashville, TN, USA
- 15 3. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA,16 USA
- 17 4. Division of Allergy, and Immunology, and Pulmonary Medicine, Department of Pediatrics,
- 18 Monroe Carrell Junior Children's Hospital at Vanderbilt, Nashville, TN, USA
- 19 5. Division of Infectious Diseases, Department of Pediatrics, Monroe Carrell Junior Children's
- 20 Hospital at Vanderbilt, Nashville, Tennessee, USA
- 6. Center for Personalized Microbiology (CPMi), Vanderbilt University Medical Center, Nashville,
 TN, USA
- 23 7. Vanderbilt Institute for Infection, Immunology and Inflammation, Vanderbilt University Medical
- 24 Center, Nashville, Tennessee, USA
- 25
- ²⁶ *These authors contributed equally to this work. Authorship position was determined by relative
- 27 contributions made to this manuscript's completion.
- 28 29

30 **Corresponding Author:**

- 31 Maribeth R. Nicholson, MD, MPH
- 32 Monroe Carell Jr. Children's Hospital at Vanderbilt
- 33 2200 Children's Way, Nashville, TN 37232
- 34 Telephone: +1 615 322 7449
- 35 E-mail: maribeth.r.nicholson@vumc.org
- 36
- 37
- 38 **RUNNING TITLE:** CF Gut Microbiome Following CFTR Modulator ELX/TEZ/IVA
- 39
- 40 41 KEY MC

41 KEY WORDS

- 42 Cystic fibrosis; CFTR modulators; microbiome; elexacaftor; ivacaftor; tezacaftor; metagenomic
- 43 sequencing; intestinal inflammation; antibiotic resistance; pediatric
- 44

It is made available under a CC-BY-ND 4.0 International license .

45 **ABSTRACT**

46 The intestinal microbiome influences growth and disease progression in children with cystic 47 fibrosis (CF). Elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA), the newest pharmaceutical 48 modulator for CF, restores function of the pathogenic mutated CFTR channel. We performed a 49 single-center longitudinal analysis of the effect of ELX/TEZ/IVA on the intestinal microbiome, 50 intestinal inflammation, and clinical parameters in children with CF. Following ELX/TEZ/IVA, 51 children with CF had significant improvements in BMI, ppFEV₁ and required fewer antibiotics for 52 respiratory infections. Intestinal microbiome diversity increased following ELX/TEZ/IVA coupled 53 with a decrease in the intestinal carriage of Staphylococcus aureus, the predominant respiratory 54 pathogen in children with CF. There was a reduced abundance of microbiome-encoded 55 antibiotic-resistance genes. Microbial pathways for aerobic respiration were reduced after 56 ELX/TEZ/IVA. The abundance of microbial acid tolerance genes was reduced, indicating 57 microbial adaptation to increased CFTR function. In all, this study represents the first 58 comprehensive analysis of the intestinal microbiome in children with CF receiving ELX/TEZ/IVA. 59

60

61 **IMPORTANCE**

62 Cystic fibrosis is an autosomal recessive disease with significant gastrointestinal 63 symptoms in addition to pulmonary complications. Prior work has shown that the intestinal 64 microbiome correlates with health outcomes in CF, particularly in children. Recently approved 65 treatments for CF, CFTR modulators, are anticipated to substantially improve the care of 66 patients with CF and extend their lifespans. Here, we study the intestinal microbiome of children 67 with CF before and after the CFTR modulator, ELX/TEZ/IVA. We identify promising 68 improvements in microbiome diversity, reduced measures of intestinal inflammation, and 69 reduced antibiotic resistance genes. We present specific bacterial taxa and protein groups 70 which change following ELX/TEZ/IVA. These results will inform future mechanistic studies to 71 understand the microbial improvements associated with CFTR modulator treatment. This study 72 demonstrates how the microbiome can change in response to a targeted medication that 73 corrects a genetic disease.

- 74
- 75
- 76
- 77
- 78

It is made available under a CC-BY-ND 4.0 International license .

79

80 **1. INTRODUCTION**

81 Cystic fibrosis (CF) is an autosomal recessive disease affecting a total of 40.000 individuals in 82 the United States (1). CF is caused by mutations in the CF transmembrane conductance 83 regulator (CFTR) gene resulting in decreased epithelial transport of chloride and bicarbonate 84 ions. These mutations result in mucus obstruction which presents with severe multi-organ 85 dysfunction, principally affecting the airways and gastrointestinal tract (2-5). The gastrointestinal 86 complications include malnutrition, dysmotility, and hepatopancreaticobiliary disease (2). 87 Importantly, nutritional status and intestinal microbiome abnormalities in children with CF have 88 been linked to growth failure, disease progression, and risk of future lung transplantation (6–11).

89 Multiple studies have demonstrated differences in the intestinal microbiome of patients with 90 CF when compared to healthy controls (8, 12–15). The CF intestinal microbiome is notably 91 inflammatory and associated with higher rates of inflammatory bowel disease (IBD) and colon 92 cancer (16–20). In infants with CF, delayed intestinal microbiome maturation has been shown to 93 influence linear growth and immune programming (8, 21). Among the most striking differences 94 compared to healthy controls is the abundance of Proteobacteria, specifically Escherichia coli, 95 and concomitant decrease in Bacteroidetes in infants with CF (8, 12, 22-24). Furthermore, 96 during acute CF pulmonary exacerbations, the intestinal microbiome is distinguishable from 97 periods of respiratory stability (15, 21, 25). Respiratory pathogens, such as Staphylococcus 98 aureus, can also be detected in CF stool samples (22, 26).

99 Over the past decade, small molecule therapies which address the primary defect in the 100 CFTR protein and rescue CFTR function in select genotypes have been developed. These 101 "CFTR modulators" have dramatically changed the trajectory of CF patient care, yielding 102 remarkable improvements in lung function, growth, and projected lifespan (27). The most recent 103 CFTR modulator formulation approved for clinical care, elexacaftor-tezacaftor-ivacaftor 104 (ELX/TEZ/IVA), includes two CFTR correctors (ELX & IVA) and one CFTR potentiator (TEZ) 105 (28). The approval of ELX/TEZ/IVA is anticipated to be the most important advancement in CF 106 therapy since CFTR was identified over 30 years ago (27, 28).

Given the progressive nature of CF, initiation of therapy in early childhood is critical to stall disease progression. ELX/TEZ/IVA was approved by the FDA for pediatric patients in 2019 (ages 12 years and older), 2021 (ages 6-11 years old), and 2023 (ages 2-5 years old). The impact of ELX/TEZ/IVA on clinical outcomes and the intestinal microbiome in children with CF requires targeted study. To date, studies examining the effects of CFTR modulators on the intestinal microbiome have been limited by the use of single modulator formulations or small

It is made available under a CC-BY-ND 4.0 International license .

113 cohort sizes (29–31). Importantly, no studies have characterized the effect of ELX/TEZ/IVA on 114 the intestinal microbiome of children with CF. We therefore undertook a longitudinal study to 115 identify changes in clinical outcomes and the intestinal microbiomes of pediatric patients 116 following the initiation of ELX/TEZ/IVA. To our knowledge, this study represents the first 117 comprehensive study of the highly effective CFTR modulator formulation ELX/TEZ/IVA on the 118 intestinal microbiome of children with CF.

119

120 **2. METHODS**

121 **2.1 Recruitment of Subjects**

122 Pediatric patients with a diagnosis of CF at Monroe Carell Jr. Children's Hospital at Vanderbilt 123 (MCJCHV) were recruited beginning in July 2017 with follow-up until October 2022. Patients 124 with the Phe508 CFTR mutation who were deemed eligible for ELX/TEZ/IVA by their 125 pulmonologist were eligible for this study. Patients previously treated with other CFTR 126 modulator regimens were permitted. Patients with pre-existing non-CF gastrointestinal disease 127 were excluded. A total of 39 participants were recruited (Table 1). Informed consent was 128 obtained from parental guardians, and assent was obtained from pediatric subjects in 129 accordance with institutional research ethics guidelines. This study was approved by the 130 MCJCHV Institutional Review Board (IRB # 200396). The lead investigators of this study had no 131 direct role in the patients' routine medical care. All study data were stored in a Research 132 Electronic Data Capture (REDCap) database per institutional guidelines (32).

133

134 **2.2 Study Timepoints**

135 Our analysis included stool samples from up to four timepoints per patient: two timepoints 136 before ELX treatment (T1 & T2) and two timepoints after initiating ELX/TEZ/IVA (T3 & T4) (Fig. 137 1B). For clinical outcomes, data was either analyzed by individual timepoints (T1-T4) or time 138 points were combined for pre-ELX/TEZ/IVA samples (T1 & T2 combined) and post-ELX-139 TEZ/IVA samples (T3 & T4 combined). Analysis of individual timepoints permitted assessment 140 of additional differences between the 6 to 12-month periods after ELX/TEZ/IVA initiation. For 141 microbiome comparisons, analysis was based on combined pre-ELX/TEZ/IVA samples (T1 & 142 T2) and post-ELX-TEZ/IVA samples (T3 & T4).

143

144 **2.3 Stool Sample Collection and DNA Extraction**

145 Stool samples were collected prior to ELX/TEZ/IVA initiation, either through targeted collection

as part of this study or from our center's biobank of CF stool samples (33, 34). Subsequent stool

It is made available under a CC-BY-ND 4.0 International license .

147 samples were collected at approximately 6- and 12-month intervals after initiation of 148 ELX/TEZ/IVA (Fig. 1A). Fecal samples were collected in sterile collection cups and refrigerated 149 until transport to the laboratory. Patients who were unable to provide a stool sample in clinic 150 were provided with an OMNIgene®•GUT stool collection kit for at home collection and 151 stabilization, returned via overnight shipping, and stored according to manufacturer 152 specifications. Aliquots of stool samples were aseptically aliquoted into cryovials in a laminar 153 flow biosafety cabinet to minimize aerosols and stored at -80°C until processing. Percent 154 predicted forced expiratory volume in one second ($ppFEV_1$) values were obtained in the 155 outpatient setting at the time of stool sample collection; the highest spirometry value of three 156 attempts was recorded. Clinical data including body mass index (BMI, percentiles), percentage 157 predicted forced expiratory volume in 1 second (ppFEV₁), medications, and laboratory values 158 were recorded for visits when a stool sample was collected. Total DNA was extracted from 114 159 stool samples using QIAamp PowerFecal Pro DNA Kits according to the manufacturer's 160 instructions. Bead beating for efficient lysis was conducted for 10 minutes. All steps, excluding 161 bead beating and centrifugation, were conducted in a laminar flow biosafety cabinet. No human 162 DNA depletion or enrichment of microbial DNA was performed. DNA yield was estimated by 163 spectrophotometry (NanoDrop[™]2000c) in parallel with ensuring satisfactory A260/A280 ratio for 164 DNA purity.

165

166 **2.4 Fecal Calprotectin Measurements**

Fecal calprotectin was measured using the Calprotectin ELISA Assay Kit (Eagle Biosciences).
Duplicate portions of stool (50-100mg) were weighed and processed according to the
manufacturer's instructions. Absorbance was measured with a SpectraMax® i3x (Molecular
Devices). Fecal calprotectin (µg/g feces) was calculated using a 7-point standard curve. The
assay's reported normal cut-off is <43.2 µg/g.</p>

172

173 **2.5 Shotgun Metagenomic Sequencing**

Sequencing libraries were prepared using Illumina® reagents as described elsewhere (35).
Pooled libraries were sequenced on NextSeq2000 to generate 150-bp paired-end reads. An
average of 13.9 million reads were produced per sample (range 9.1 to 30.1 million). Sequencing
adaptors and low-quality sequences were trimmed with fastq-mcf from ea-utils-1.1.2.779 using
default parameters (Supplementary Methods) (36).

179

180 **2.6 Taxonomic and Functional Profiling of Metagenomic Sequence Data**

It is made available under a CC-BY-ND 4.0 International license .

181 Species abundances were determined with MetaPhIAn4 following read alignment to the 182 MetaPhlan4 database (37). Diversity metrics were calculated with the vegan R package (38) 183 and plotted with gpplot2. A weighted UniFrac distance matrix was constructed with the 184 MetaPhIAn R script "calculate_unifrac". Functional profiling was conducted with HUMAnN 3.0 185 with mapping to UniRef90 gene-families and MetaCyc metabolic pathways (39-41). UniRef90 186 gene-families were reformatted into KEGG orthology (KO) groups using the HUMAnN command 187 "humann_regroup_table". In total, we identified 722 species, 526 MetaCyc pathways, and 8634 188 distinct KO groups annotations in the 114 samples. All functional annotations were normalized 189 using the HUMAnN command "humann renorm table --units cpm". Antibiotic resistance genes 190 were identified by ShortBRED (42) with the reference Comprehensive Antibiotic Resistance 191 Database (CARD version 2017) (43). ARG abundance was calculated as reads per kilobase of 192 reference sequence per million sample reads (RPKM).

193

2.7 Microbial Dysbiosis Index

195 The Microbial Dysbiosis Index (MD-index) was calculated as the log10 of the ratio of the relative 196 abundance of taxa which were previously positively and negatively associated with newly 197 diagnosed pediatric Crohn's disease (44). Specifically, the includes numerator 198 Enterobacteriaceae. Pasteurellaceae, Fusobacteriaceae, Neisseriaceae, Veillonellaceae, 199 Gemellaceae: the denominator includes Bacteroidales, Clostridiales (excluding Veillonellaceae), 200 Erysipelotrichaceae, and Bifidobacteriaceae. Higher indices correspond to a greater 201 inflammatory taxonomic profile. The MD-index has been previously applied to stool samples of 202 children with CF (14, 45).

203

204 **2.8 Differential Abundance Testing**

205 We used MaAsLin2 (Microbiome Multivariable Associations with Linear Models, Maaslin2 R 206 package) to identify differentially abundant features (46). We included ELX/TEZ/IVA, age, and 207 recent antibiotic exposure as fixed effects. Subject ID was specified as a random effect due to 208 multiple samples from the same subject. Species, KEGG orthologs, and MetaCyc pathways 209 detected at least 10% of samples were tested (i.e., prevalence = 0.1); no minimum abundance 210 was specified. Abundances were log transformed within the MaAsLin2 function. The general 211 linear "LM" model was used. MaAsLin2 coefficients are equivalent to log2(FoldChange). The 212 Benjamini-Hochberg procedure was used to correct P values, and corrected P values are 213 reported as False Discovery Rates (FDR).

214

It is made available under a CC-BY-ND 4.0 International license .

215 **2.9 Statistical Analyses**

216 Statistical analyses were conducted using GraphPad Prism 9 and R (version 4.2.1) software.

- 217 Details of the statistical tests used and the significance thresholds are presented in the figure
- 218 legends. All box-plot graphs are defined as: center line—median; box limits—upper and lower
- 219 quartiles; whiskers—1.5× interquartile range.
- 220

221 **2.10 Reproducibility and Data Availability**

The results can be reproduced using raw sequence data that are available on NCBI-Genbank databases under BioProject PRJNA948536 or using processed data in the Supplementary Dataset 1. Bioinformatic code is available within the repository https://github.com/reaset41/CF-GI-Microbiome-ELX-TEZ-IVA.

226

3. RESULTS

228 **3.1 Study Cohort and Stool Sample Collection**

229 Stool samples were collected from a total of 39 children with CF (Table 1). The median 230 (IQR) age of participants at the time of ELX/TEZ/IVA initiation was 9.86 years old (8.87, 12.15) 231 and 53.4% were male. Of these, 35.9% (14/39 subjects) had CFTR modulator use (at any time) 232 before ELX/TEZ/IVA. Patients provided an average of 2.92 stool samples with all patients 233 providing at least one stool sample prior to starting ELX/TEZ/IVA (T1 median= 33.6 months 234 before ELX/TEZ/IVA initiation, IQR 28.6, 36.7 months and T2 median=0.64 months before 235 ELX/TEZ/IVA initiation, IQR 0.13, 2.2 months). Subsequent stool samples were collected at 236 approximately 6- and 12-month intervals (T3 median=5.97 months, IQR 5.38, 6.92 months and 237 T4 median=12.39 months, IQR 11.1, 13.1 months). There was a total of 114 stool samples with 238 53 samples before ELX/TEZ/IVA therapy and 61 samples after ELX/TEZ/IVA treatment (Fig. 1A 239 & S2). Of the 53 samples collected pre-ELX/TEZ/IVA, 8 samples (15%) were collected while the 240 patient was receiving an alternative CFTR modulator (Supplementary Dataset 1).

241

242 **3.2 Clinical Improvement after ELX/TEZ/IVA**

To determine our cohort's clinical response to ELX/TEZ/IVA, we compared clinical metrics from before and after ELX/TEZ/IVA initiation. Both BMI percentile and ppFEV₁ increased in the timepoints after ELX/TEZ/IVA compared to pre-ELX/TEZ/IVA timepoints (Fig. 1C-D & S1A-B). Median BMI percentile increased from the 54th percentile to the 67th percentile after ELX/TEZ/IVA (Fig. 1D). Likewise, there was a mean change in ppFEV₁ of 12.3 percentage points (95% CI 6.7-17.8) before and after ELX/TEZ/IVA (Fig. 1C). Between 6- and 12-months

It is made available under a CC-BY-ND 4.0 International license .

after ELX/TEZ/IVA, there was no further significant improvement in either BMI or ppFEV₁ (Fig.
S1A-B, T3 & T4). Consistent with increased BMI, weight percentile increased after ELX/TEZ/IVA
(Fig. S1C). Height percentile increased between T2 and both T3 and T4 (Fig. S1D, P=0.013,
P=0.026, respectively), though not between T1 and T3 & T4. Total antibiotic days per patient
were aggregated and decreased from a median of 22.5 days per 6-months before ELX/TEZ/IVA
to 0 antibiotic days per 6-months after ELX/TEZ/IVA (Fig. 1E, P<0.0001).

255

256 **3.3 Microbiome Diversity Increases After ELX/TEZ/IVA**

257 From shotgun metagenomic sequencing on 114 stool samples, we compared measures 258 of microbiome taxonomy and diversity. In contrast to previously published CF microbiome 259 datasets of infants (8, 22), our dataset of older children was dominated by the phylum 260 Firmicutes with minimal Proteobacteria (Fig. 2A and Supplementary Dataset 1). Alpha diversity, 261 as measured by the Shannon index and richness (observed species), significantly increased 262 following ELX/TEZ/IVA (Fig. 2B-C, P=0.021 and P=0.026, respectively). The number of species 263 observed increased from a median (IQR) of 83 (62, 115) species before ELX/TEZ/IVA to 109 264 (82,125) species after ELX/TEZ/IVA (Fig. 2B). The cumulative increases in alpha diversity were 265 not significantly different when comparing between the four timepoints individually (Fig. S2A-B). 266 and there were no differences in overall community composition (beta-diversity) before and after 267 ELX/TEZ/IVA (Fig. S2C-D).

268 To determine the effect of prior CFTR modulator treatment besides ELX/TEZ/IVA, we 269 compared diversity metrics between modulator naïve samples (samples=45) and samples 270 collected while subjects were receiving another CFTR modulator (samples=8) before 271 ELX/TEZ/IVA. Samples collected while subjects were receiving another CFTR modulator had 272 similar diversity to modulator naïve samples (Fig. S3A-B). Following ELX/TEZ/IVA, samples 273 from subjects who had previously received another modulator (samples=20) had similar 274 improvements in microbiome diversity to samples from subjects who had not previously 275 received another modulator (samples=41), indicating that the residual effects of another 276 modulator did not influence microbiome diversity improvement on ELX/TEZ/IVA (Fig. S3C-D).

To determine the influence of antibiotic exposure on microbiome diversity measures regardless of ELX/TEZ/IVA status, we categorized patient stool samples as having received antibiotics within the six-months prior to stool sample collection (samples=62) or no antibiotic receipt (samples=52). Recent antibiotic exposure significantly impacted alpha diversity measures reducing Shannon diversity and richness (Fig. 2D-E). Likewise, population structure

It is made available under a CC-BY-ND 4.0 International license .

282 (beta-diversity) was significantly different between samples with and without recent antibiotic

- 283 exposure (Fig. S2E, permutational multivariate analysis of variance [PERMANOVA]=0.003).
- 284

285 **3.4 Microbiome Encoded Antibiotic Resistance Genes Decrease After ELX/TEZ/IVA**

286 As discussed above, patients required far fewer antibiotics after starting ELX/TEZ/IVA 287 (Fig. 1E & S4A). Since the intestinal microbiome is a reservoir of antibiotic resistant genes 288 (ARGs) (47), we compared the number and type of intestinal ARGs before and after 289 ELX/TEZ/IVA initiation. Across the 114 samples, we detected a total of 309 unique ARGs. The 290 median number of unique ARGs nominally decreased from a median 86 ARGs (IQR 40, 96) 291 before ELX/TEZ/IVA to a median 68 ARGs (IQR 38, 90) after ELX/TEZ/IVA (Fig. S4B, P=0.31). 292 ARG abundance decreased from a median of 1180 RPKM (IQR 815.4, 1761.1) to 829 RPKM 293 (IQR 460.5, 1299.0) (Fig. 3A, P=0.0097) though this effect was likely mediated by reduced 294 antibiotic use.

295 Next, we aggregated the relative abundance of ARGs by antibiotic class to which they 296 confer resistance (Fig. 3B). The abundance of ARGs conferring resistance to peptide antibiotics 297 and ungrouped antibiotics ("Other") significantly decreased after ELX/TEZ/IVA (Fig. 3B & S4C-298 E, P=0.012, P=0.022 respectively). The most prevalent antibiotics within the peptide ARG class 299 included arnA (samples=72/114), yojl (samples=71/114), pmrF (samples=74/114) and pmrC 300 (samples=71/114). arnA, pmrF and pmrC modify Lipid A on bacterial cells to repel cationic 301 peptide antibiotics, whereas yoil is a peptide efflux pump. The most prevalent ARGs within the 302 "Other" group were fabl (samples=84/114), gadE (samples=78/114), and EF-Tu mutations 303 (samples=75/114). These ARGs or mutations confer resistance to isoniazid/disinfecting agents 304 (fabl), acid resistance and efflux pump (gadE), and elfamycin (EF-Tu). Despite being the most 305 prevalent, none of these ARGs were independently altered in abundance following 306 ELX/TEZ/IVA (Fig. S4D & S4F).

307

308 **3.5 Alterations to Specific Bacterial Taxa Following ELX/TEZ/IVA**

To determine whether specific bacterial taxa change following ELX/TEZ/IVA treatment, we used MaAsLin2 (Microbiome Multivariable Associations with Linear Models) to identify differentially abundant microbial taxa (46). No phyla were differentially abundant following ELX/TEZ/IVA (Fig. 2A & Table S4). At a granular taxonomic level, seventeen species were differentially abundant between samples before and after ELX/TEZ/IVA (FDR<0.1, Fig. 4A and Table S3), with eleven species increasing in abundance after ELX/TEZ/IVA, and six species decreasing. The three species with the lowest FDR and, therefore, highest reliability were

It is made available under a CC-BY-ND 4.0 International license .

316 Butyricicoccus SGB14985, S. aureus, and Roseburia faecis (Fig. 4A-B). Butyricicoccus 317 SGB14985, an uncultivated species, was decreased in abundance following ELX/TEZ/IVA (fold 318 change 0.16, FDR=0.022). Roseburia faecis was increased in abundance following 319 ELX/TEZ/IVA (fold change 7.35, FDR=0.025) and negatively correlated with recent antibiotic 320 exposure (Fig. S5A, fold change 0.20, FDR=0.086). The intestinal tract has immunological 321 cross-talk between the separate but similarly structured mucosal environment of the lung, 322 deemed the gut-lung axis (20). Since the intestinal tract can harbor similar respiratory 323 pathogens in patients with CF (15, 48, 49), we performed focused analysis of CF pathogens. S. 324 aureus, the predominant respiratory pathogen in children with CF (50), was decreased in 325 abundance after ELX/TEZ/IVA (Fig. 4A-B, fold change 0.40, FDR=0.042). Other members of the 326 respiratory microbiota which are frequently detected in the intestines (14, 15)—specifically the 327 genera Haemophilus, Prevotella, Streptococcus, Veillonella-did not significantly change after 328 ELX/TEZ/IVA initiation (Fig. S5B). *Pseudomonas aeruginosa*, an additional respiratory pathogen 329 of importance in CF, was detected in only two of the 114 stool samples. Furthermore, fungal 330 taxa were only identified in 8/114 samples (Supplementary Dataset 1).

331

332 3.6 Intestinal Inflammation Decreases After ELX/TEZ/IVA

333 Fecal calprotectin was measured across the four timepoints and markedly decreased 334 following ELX/TEZ/IVA (Fig. 5A & S5A). Overall, mean fecal calprotectin decreased from 109 335 μ g/g before ELX/TEZ/IVA to 44.8 μ g/g for a mean decrease of 64.2 μ g/g (95% CI -16.1, -112.3, 336 Fig. 5A). We then computed the microbial dysbiosis index (MD-index), a ratio of bacterial taxa 337 positively and negatively associated with newly diagnosed pediatric Crohn's disease, to assess 338 the relationship between intestinal inflammation and specific microbial signatures (44). We 339 noted a nominal reduction in the MD-index following ELX/TEZ/IVA (Fig. 5B, P=0.068), which 340 was less pronounced when comparing samples from patients with recent antibiotic exposure 341 and those without (Fig. 5C, P=0.77).

342

343 **3.7 Microbiome Functional Changes Reveal Specific Disease-Relevant Changes**

From the 114 stool samples, alignment of sequencing reads to known microbial proteins and pathways identified 8634 KEGG orthology (KO) protein groups and 526 MetaCyc metabolic pathways, consistent with prior studies of the intestinal microbiota (51). There were 249 KO groups differentially abundant with respect to ELX/TEZ/IVA use (MaAsLin2 FDR<0.25, Fig. 5D & Table S6). Strikingly, a common thread among differentially abundant KO groups was a decreased abundance of genes encoding oxidative phosphorylation functions following

It is made available under a CC-BY-ND 4.0 International license .

350 ELX/TEZ/IVA (Fig. 5D). Seven of the top 10 most differentially abundant KO groups were 351 components of the electron transport chain (Fig. 5D & S5B and Table S7) and included NADH-352 ubiquinone oxidoreductases (e.g., K03883, K03881, K03884, & K03880), F-type ATPase 353 subunits (e.g., K02125), and cytochrome c oxidase subunits (e.g., K02262, K02261, & K02256). 354 The taxa contributing to oxidative phosphorylation KO groups were not consistently annotated 355 by HUMAnN (Fig. S6C and Table S10). This indicates that a specific taxonomic signature was 356 not responsible for the reduced abundance of oxidative phosphorylation KO groups (Fig. S6C). 357 These results were corroborated by MaAsLin2 differential abundance testing of MetaCyc 358 pathways. Sixty-four MetaCyc pathways were differentially abundant with respect to 359 ELX/TEZ/IVA use (MaAsLin2 FDR<0.25, Fig. 5E & S7, Table S9). Two of these pathways 360 corresponded to aerobic respiration (PWY-3781 and PWY-7279). Differential abundance of 361 anaerobic energy metabolism pathways showed discordant results with one pathway increased in abundance following ELX/TEZ/IVA (PWY-7383), and two pathways decreased in abundance 362 363 (PWY-7389 and PWY-7384) following ELX/TEZ/IVA (Fig. S7 and Table S9). Thirteen amino 364 acid biosynthesis pathways were universally prevalent in all stool samples (114/114) and 365 significantly increased in abundance following ELX/TEZ/IVA (Fig. 5E and Table S9, FDR<0.25). 366 This indicates increased biosynthetic capacity of the intestinal microbiome following 367 ELX/TEZ/IVA.

368 Furthermore, multiple pathways related to nucleobase and nucleotide metabolism were 369 differentially abundant following ELX/TEZ/IVA. Pyrimidine deoxyribonucleotide biosynthesis 370 pathways were reduced in abundance following ELX/TEZ/IVA (PWY-7184 & PWY-6545) 371 whereas a pyrimidine ribonucleotides biosynthesis pathway was increased in abundance 372 (PWY0-162, Fig.S7 and Table S9). While these general pyrimidine deoxyribonucleotide 373 biosynthesis pathways were reduced in abundance, specific pathways for thiamine biosynthesis 374 (PWY-7357) and two uridine-monophosphate biosynthesis pathways (PWY-7790 & PWY-7791) 375 were significantly increased in abundance following ELX/TEZ/IVA. An anaerobic pathway for 376 purine degradation was increased in abundance following ELX/TEZ/IVA (P164-PWY). Three 377 pathways related to allantoin degradation were significantly reduced in abundance following 378 ELX/TEZ/IVA (PWY-5692, PWY0-41 & URDEGR-PWY, Fig. S7 and Table S9).

Another intriguing observation was the reduced abundance of KO groups involved in acid tolerance and transport following ELX/TEZ/IVA (Fig. 5D). KO groups involved in organic acid transport (e.g., K03290 & K23016) and proton-symporters (e.g., K11102 & K03459) were reduced in abundance following ELX/TEZ/IVA. Likewise, an acidity-responsive transcriptional

It is made available under a CC-BY-ND 4.0 International license .

regulator (K03765, *cadC*) was decreased in abundance following ELX/TEZ/IVA (Fig. 5D and
 Table S7, fold change 0.42, FDR=0.27).

385

4. DISCUSSION

387 ELX/TEZ/IVA has changed the trajectory of CF patient care and dramatically improved 388 clinical outcomes. Nutritional status and components of the intestinal microbiome are strong 389 predictors of future clinical outcomes, particularly in children with CF (6-8). We therefore sought 390 to determine the effects of ELX/TEZ/IVA on intestinal inflammation and the intestinal 391 microbiome in children with CF. Herein, we present a comprehensive longitudinal 392 characterization of the intestinal microbiome in children with CF treated with ELX/TEZ/IVA. We 393 identified widespread changes to the intestinal microbiome after ELX/TEZ/IVA including 394 taxonomic composition, reduced carriage of ARGs, and altered microbiota metabolic functions.

395 Although randomized controlled trials demonstrated that ELX/TEZ/IVA was safe and 396 effective, there are limited post-approval clinical data, particularly in children over two years old 397 (52–56). BMI and ppFEV₁ are useful markers of clinical response to CFTR modulator treatment 398 in children (57). Our cohort demonstrated significant improvement in ppFEV₁ and BMI percentile 399 within six-months of starting ELX/TEZ/IVA, with no additional differences at later time points 400 (Fig. S1A-B). This is consistent with prior clinical trial and real-world data showing the greatest 401 impact on nutritional status and anthropometric parameters immediately after ELX/TEX/IVA 402 therapy initiation with subsequent plateau without regression in children (52, 56, 58). Prior 403 baseline BMI, particularly underweight status, has been predicted to be a major determinant of 404 increase in weight gain in patients with CF treated with ELX/TEZ/IVA (59). Furthermore, 405 between the timepoint immediately before ELX/TEZ/IVA initiation (T2) and post-ELX/TEZ/IVA 406 timepoints (T3 & T4), there was a significant increase in height percentile (Fig. S1D). This 407 suggests that CFTR modulator therapy may improve linear growth in children with CF. In sum, 408 these results support the clinical responsiveness of children with CF to ELX/TEZ/IVA.

409 The gastrointestinal microbiome influences whole-body physiology. CF intestinal 410 microbiome abnormalities begin in infancy, diverging from healthy controls soon after birth (8, 411 14, 15, 21–23). Intriguingly, the microbiome of patients with CF resembles that of patients with 412 IBD, a group with a characteristically perturbed intestinal microbiome (12, 45, 60). Considerable 413 prior research has characterized the development of the CF intestinal microbiome in infants (8, 414 13-15, 21-23). Less information exists about the CF intestinal microbiome in children and 415 adolescents (13, 24, 26, 61-65). A consistent finding is that high levels of the phylum 416 Proteobacteria, specifically the species Escherichia coli, define the infant CF intestinal

It is made available under a CC-BY-ND 4.0 International license .

417 microbiome (12, 22). The abundance of Proteobacteria decreases with age in young children 418 with CF (14, 22). In our dataset of older children with CF, Proteobacteria comprised a minority of 419 the identified bacteria (Fig. 2A). In turn, the relative abundance of the phylum Firmicutes is 420 increased in our cohort, likely representing a more stable "adult-like" microbiome.

421 Direct comparison of our results to studies containing healthy controls is difficult given 422 different sampling and sequencing methodologies. Notably, although our study identified subtle 423 changes in the intestinal microbiome after initiation of ELX/TEZ/IVA in children with CF, the post-ELX/TEZ/IVA intestinal microbiome remains significantly altered from what has been 424 425 described in healthy children. Compared to healthy children, the intestinal microbiome of 426 children with CF is delayed in development and exhibits decreased microbial diversity relative to 427 healthy controls throughout childhood and adolescence (22, 24, 63). Among the most consistent 428 differences between healthy controls and patients with CF is reduced abundance of the phylum 429 Bacteroidetes in patients with CF (13, 20, 61, 63, 66). In our dataset, Bacteroidetes remained 430 depleted post-ELX/TEZ/IVA (Fig. 2A and Table S4). Likewise, Shannon diversity remained 431 below that of similarly-aged healthy controls (24, 63), as discussed henceforth.

432 In our cohort, alpha diversity, as measured by the Shannon index and richness (observed 433 species), significantly increased following ELX/TEZ/IVA (Fig. 2B-C). These results demonstrate 434 modest but statistically significant differences in an older cohort of children with CF, whose 435 microbiome resembles that of more of a stable "adult-like" microbiome. The difference in the 436 median Shannon diversity was increased 0.29 after ELX/TEZ/IVA (Fig. 2B). In contrast, a 437 similarly aged cohort of children with CF exhibited a median ~1.0 reduced Shannon index 438 compared to healthy controls in the same study (24). Thus, while our cohort exhibited significant 439 increases in Shannon diversity, it is unlikely that this magnitude of increase restores the 440 diversity to that of similarly aged healthy controls. This is consistent with the notion that "adult-441 like" intestinal microbiota are remarkably stable and resilient to intervention (67-69). As CFTR 442 modulator formulations are approved for younger children, particularly infants for whom the 443 microbiome is still developing, studying the effects of CFTR modulators on the developing 444 intestinal microbiome will be an important research endeavor and may show more substantial 445 differences.

In children with CF, markers of intestinal inflammation correlate with growth failure (11, 24). Moreover, intestinal inflammation in patients with CF is linked to higher rates of IBD and colorectal cancer in patients with CF (16, 17, 70). Fecal calprotectin, a laboratory marker of intestinal inflammation (71–73), significantly decreased following ELX/TEZ/IVA (Fig. 5A), corroborating prior reports in the PROMISE and RECOVER cohorts (74, 75). Using a dysbiosis

It is made available under a CC-BY-ND 4.0 International license .

451 index of bacterial taxa correlated with pediatric Crohn's disease (44), we identified that this 452 dysbiosis index nominally decreased following ELX/TEZ/IVA initiation (Fig. 5B). The decrease in 453 the median MD-index was 0.166 before and after ELX/TEZ/IVA. The median post-ELX/TEZ/IVA 454 MD-index was lower (i.e. reduced inflammatory taxa) than that of healthy controls in the original 455 publication describing the MD-index (44). This suggests that the magnitude of decrease in the 456 MD-index in our study may be biologically meaningful. Furthermore, the difference between pre-457 and post-ELX/TEZ/IVA (Fig. 5B) was more pronounced than in samples with and without recent 458 antibiotic exposure (Fig. 5C). This suggests that this effect may be specific to ELX/TEZ/IVA 459 treatment, and not due to reduced antibiotic use. At the species level, the butyrate-producing 460 species Roseburia faecis was significantly enriched following ELX/TEZ/IVA (Fig. 4A-B). Prior 461 studies have identified R. faecis as reduced in abundance in patients with CF (20, 76-78). In 462 parallel, we detected reduced abundance of genes involved in oxygen-dependent metabolism 463 following ELX/TEZ/IVA (Fig. 5D-E). Intestinal inflammation is characterized by a shift towards 464 oxygen-dependent microbiota metabolism, perpetuating a cycle of inflammatory damage (79-465 81). From multiple lines of evidence, our results suggest that ELX/TEZ/IVA reduces intestinal 466 inflammation in children with CF.

467 Respiratory infections require frequent antibiotics in patients with CF. Some respiratory 468 pathogens also colonize the intestinal tract and temporally correlate with respiratory colonization 469 (15, 48, 49). S. aureus is among the first pathogens to colonize the respiratory tract and cause 470 infections in children with CF (50). We detected reduced intestinal abundance of S. aureus 471 following ELX/TEZ/IVA (Fig. 4A-B). Antibiotic exposure in patients with CF has been associated 472 with increased intestinal carriage of antibiotic resistant bacteria compared to healthy controls 473 which are a poor prognostic factor (82-84). Following ELX/TEZ/IVA, patients in our cohort 474 required far fewer antibiotics (Fig. 1E). In turn, we detected reduced intestinal abundance of 475 ARGs (Fig. 2E). These results indicate disease-relevant taxonomic changes to the intestinal 476 microbiome following ELX/TEZ/IVA, as well as reduced ARGs.

The CFTR channel permits transepithelial movement of bicarbonate (HCO3⁻) and chloride (Cl⁻) (5). Intestinal pH is lower in patients with CF due to the lack of neutralizing bicarbonate (85) yet increases with CFTR modulator treatment, consistent with increased CFTR activity in the intestinal tract (86). We observed a reduced abundance of microbial protein groups associated with acid tolerance (Fig. 5D), consistent with microbial adaptation to increased CFTR channel function in the intestines. These results display physiologically intuitive functional changes to the microbiome post-ELX/TEZ/IVA. As CFTR modulators become the

484 mainstay of treatment for CF, further research will be necessary to mechanistically describe the
 485 effects of CFTR modulators on gastrointestinal function.

486 Our study is strengthened by longitudinal sampling over a five-year period combined 487 with the real-world use of ELX/TEZ/IVA. Using shotgun metagenomic sequencing, we 488 comprehensively compared microbiota differences before and after ELX/TEZ/IVA. Sampling of 489 the intestinal microbiome over extended periods will be important to uncover additional long-490 term improvements to the microbiome. Similarly, further research is necessary to delineate the 491 effects of ELX/TEX/IVA on the interconnected respiratory and intestinal microbiomes. Although 492 our study was limited by the single-center focus, our cohort mirrors the overall CF pediatric 493 population in clinical and demographic factors (Table 1). Our study lacks untreated CF controls 494 or healthy controls, which would allow for additional comparisons.

In summary, our results indicate that the CFTR modulator ELX/TEZ/IVA alters the intestinal microbiome in children with CF. We identified taxonomic and functional changes to the intestinal microbiome that represent improvements to CF intestinal microbiome structure and function. Our results also support that CFTR modulators reduce intestinal inflammation in children with CF.

500

501 AUTHOR CONTRIBUTIONS (CRediT author statement)

502 SAR: Investigation, Methodology, Data Curation, Formal analysis, Writing - Original Draft

- 503 RB: Conceptualization, Funding Acquisition, Investigation, Data Curation, Writing Original Draft
- 504 AW: Investigation, Software
- 505 KP: Investigation
- 506 JS: Investigation
- 507 AGS: Supervision, Writing Review & Editing
- 508 RFB: Supervision, Writing Review & Editing
- 509 KME: Supervision, Writing Review & Editing
- 510 SJS: Investigation, Data Curation, Software, Writing Review & Editing
- 511 MH: Supervision, Writing Review & Editing
- 512 MRN: Conceptualization, Funding Acquisition, Investigation, Supervision, Writing Original Draft 513

514 ACKNOWLEDGEMENTS AND FUNDING

- 515 We would like to express our sincere appreciation to the patients and their families who
- 516 enthusiastically participated in this study. We would like to thank our advanced practitioner and
- 517 nursing colleagues from the Pediatric Pulmonology clinic at the Monroe Carrell Jr. Children's

It is made available under a CC-BY-ND 4.0 International license .

- 518 Hospital at Vanderbilt for their collegiality and assistance with this study. This work was
- 519 supported, in part, by National Institutes of Health (NIH) grants T32DK007673 (RB),
- 520 K23AI156132 (MRN), F30AI169748 (SAR), T32GM007347 (SAR), and P30DK089507 (SJS);
- 521 the Cystic Fibrosis Foundation (SINGH19R0 to SJS) and the Thrasher Research Fund (RB and
- 522 MRN).
- 523

524 **CONFLICTS OF INTERESTS**

- 525 All authors declare that they have no conflicts of interest relevant to this work.
- 526

527 DATA AVAILABILITY

- 528 All sequence data derived from this work are publicly available in NCBI-Genbank databases
- 529 under BioProject PRJNA948536. All processed data and code used for bioinformatic analysis is
- 530 available within the repository: https://github.com/reaset41/CF-GI-Microbiome-ELX-TEZ-IVA.
- 531

532 AUTHOR ORCID IDs:

- 533 SAR: 0000-0002-7791-1641
- 534 RB: 0000-0002-6689-5658
- 535 AW: 0000-0002-5202-1108
- 536 KP: 0000-0003-1454-6381
- 537 AGS: 0000-0002-5495-1237
- 538 RFB: 0000-0003-3632-4587
- 539 KME: 0000-0003-3912-9832
- 540 SJS: 0000-0001-8355-6992
- 541 MH: 0000-0003-4249-8997
- 542 MRN: 0000-0003-3941-5599
- 543

544 **REFERENCES**

- 2022. CF Foundation Estimates Increase in CF Population. Cystic Fibrosis Foundation.
 https://www.cff.org/news/2022-07/cf-foundation-estimates-increase-cf-population.
- 547 Retrieved 10 April 2023.
- Moshiree B, Freeman AJ, Vu PT, Khan U, Ufret-Vincenty C, Heltshe SL, Goss CH,
 Schwarzenberg SJ, Freedman SD, Borowitz D, Sathe M. 2022. Multicenter prospective
 study showing a high gastrointestinal symptom burden in cystic fibrosis. Journal of Cystic
 Fibrosis https://doi.org/10.1016/j.jcf.2022.10.006.
- De Lisle RC, Borowitz D. 2013. The cystic fibrosis intestine. Cold Spring Harb Perspect Med 3:1–18.
- 4. Kreda SM, Davis CW, Rose MC. 2012. CFTR, mucins, and mucus obstruction in cystic
 fibrosis. Cold Spring Harb Perspect Med 2.
- 556 5. Elborn JS. 2016. Cystic fibrosis. The Lancet 388:2519–2531.

557	6.	Steinkamp G, Wiedemann B. 2002. Relationship between nutritional status and lung
558		function in cystic fibrosis: Cross sectional and longitudinal analyses from the German CF
559		quality assurance (CFQA) project. Thorax 57:596–601.
560	7.	Ashkenazi M, Nathan N, Sarouk I, Aluma BEB, Dagan A, Bezalel Y, Keler S, Vilozni D,
561		Efrati O. 2019. Nutritional Status in Childhood as a Prognostic Factor in Patients with
562		Cystic Fibrosis. Lung https://doi.org/10.1007/s00408-019-00218-3.
563	8.	Hayden HS, Eng A, Pope CE, Brittnacher MJ, Vo AT, Weiss EJ, Hager KR, Martin BD,
564		Leung DH, Heltshe SL, Borenstein E, Miller SI, Hoffman LR. 2020. Fecal dysbiosis in
565		infants with cystic fibrosis is associated with early linear growth failure. Nat Med 26:215–
566		221.
567	9.	Rogers GB, Carroll MP, Hoffman LR, Walker AW, Fine DA, Bruce KD. 2010.
568		Comparing the microbiota of the cystic fibrosis lung and human gut. Gut Microbes 1:85–
569		93.
570	10.	Héry-arnaud G, Boutin S, Cuthbertson L, Elborn SJ, Tunney MM. 2019. The lung and gut
571		microbiome: what has to be taken into consideration for cystic fibrosis ? Journal of
572		Cystic Fibrosis 18:13–21.
573	11.	Dhaliwal J, Leach S, Katz T, Nahidi L, Pang T, Lee JM, Strachan R, Day AS, Jaffe A, Ooi
574		CY. 2015. Intestinal inflammation and impact on growth in children with cystic fibrosis. J
575		Pediatr Gastroenterol Nutr 60:521–526.
576	12.	Hoffman LR, Pope CE, Hayden HS, Heltshe S, Levy R, McNamara S, Jacobs MA,
577		Rohmer L, Radey M, Ramsey BW, Brittnacher MJ, Borenstein E, Miller SI. 2014.
578		Escherichia coli dysbiosis correlates with gastrointestinal dysfunction in children with
579		cystic fibrosis. Clinical Infectious Diseases 58:396–399.
580	13.	Manor O, Levy R, Pope CE, Hayden HS, Brittnacher MJ, Carr R, Radey MC, Hager KR,
581		Heltshe SL, Ramsey BW, Miller SI, Hoffman LR, Borenstein E. 2016. Metagenomic
582		evidence for taxonomic dysbiosis and functional imbalance in the gastrointestinal tracts of
583		children with cystic fibrosis. Sci Rep 6:1–9.
584	14.	Price CE, Hampton TH, Valls RA, Barrack KE, O'Toole GA, Madan JC, Coker MO.
585		2023. Development of the intestinal microbiome in cystic fibrosis in early life. mSphere
586		https://doi.org/10.1128/msphere.00046-23.
587	15.	Madan JC, Koestle DC, Stanton BA, Davidson L, Moulton LA, Housman ML, Moore JH,
588		Guill MF, Morrison HG, Sogin ML, Hampton TH, Karagas MR, Palumbo PE, Foster JA,
589		Hibberd PL, O'Toole GA. 2012. Serial analysis of the gut and respiratory microbiome in
590		cystic fibrosis in infancy: Interaction between intestinal and respiratory tracts and impact
591		of nutritional exposures. mBio 3.
592	16.	Hadjiliadis D, Khoruts A, Zauber AG, Hempstead SE, Maisonneuve P, Lowenfels AB,
593		Braid AL, Cullina J, Daggett A, Fink A, Gini A, Harron PF, Lansdorp-Vogelaar I,
594		Lieberman D, Liou T, Lomas P, Marshall B, Meyer K, Rustgi A, Shaukat A, Sabadosa K.
595		2018. Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations.
596	17	Gastroenterology 154:736-745.e14.
597	17.	Hegagi M, Aaron SD, James P, Goel R, Chatterjee A. 2017. Increased prevalence of
598	10	colonic adenomas in patients with cystic fibrosis. Journal of Cystic Fibrosis 16:759–762.
399	18.	Schwarzenberg SJ, Wielinski CL, Shamieh I, Carpenter BLM, Jessurun J, Weisdorf SA,
600		Warwick WJ, Sharp HL. 1995. Cystic fibrosis-associated colitis and fibrosing
001		colonopatny. J Pediatr 12/:363–3/0.

602 19. Burton S, Hachem C, Abraham J. 2021. Luminal Gastrointestinal Manifestations of Cystic 603 Fibrosis. Curr Gastroenterol Rep 23. Price CE, O'Toole GA. 2021. The gut-lung axis in cystic Fibrosis. J Bacteriol. American 604 20. 605 Society for Microbiology https://doi.org/10.1128/JB.00311-21. 606 21. Antosca KM, Chernikova DA, Ruoff KL, Li K, Guill MF, MacKenzie TA, Dorman DB, 607 Moulton LA, Williams MA, Aldrich BJ, Yuan IH, Karagas MR, O'Toole GA, Madan JC. 608 2019. Altered Stool Microbiota of Infants with Cystic Fibrosis Shows Reduction in 609 Genera Associated with Immune Programming. J Bacteriol 201:1-15. 610 22. Salerno P, Verster AJ, Valls RA, Barrack KE, Price CE, Madan JC, O'Toole GA, Ross 611 BD. 2023. Persistent delay in maturation of the developing gut microbiota in infants with 612 cystic fibrosis. bioRxiv https://doi.org/10.1101/2023.05.02.539134. 613 23. Kristensen M, Prevaes SMPJ, Kalkman G, Tramper-Stranders GA, Hasrat R, de Winter-614 de Groot KM, Janssens HM, Tiddens HA, van Westreenen M, Sanders EAM, Arets B, 615 Keijser B, van der Ent CK, Bogaert D. 2020. Development of the gut microbiota in early 616 life: The impact of cystic fibrosis and antibiotic treatment. Journal of Cystic Fibrosis 617 19:553-561. 618 24. Coffey MJ, Nielsen S, Wemheuer B, Kaakoush NO, Garg M, Needham B, Pickford R, Ja 619 A, Thomas T, Chee Y. Ooi. 2019. Gut Microbiota in Children With Cystic Fibrosis: A 620 Taxonomic and Functional Dysbiosis. Sci Rep 9:1–14. 621 25. Hoen AG, Li J, Moulton LA, O'Toole GA, Housman ML, Koestler DC, Guill MF, Moore 622 JH, Hibberd PL, Morrison HG, Sogin ML, Karagas MR, Madan JC. 2015. Associations 623 between gut microbial colonization in early life and respiratory outcomes in cystic 624 fibrosis. Journal of Pediatrics 167:138-147.e3. 625 Vernocchi P, Chierico F Del, Russo A, Majo F, Rossitto M, Valerio M, Casadei L, Storia 26. 626 A La, De Filippis F, Rizzo C, Manetti C, Paci P, Ercolini D, Marini F, Fiscarelli EV, 627 Dallapiccola B, Lucidi V, Miccheli A, Putignani L. 2018. Gut microbiota signatures in 628 cystic fibrosis: Loss of host CFTR function drives the microbiota enterophenotype. PLoS 629 One 13:1–23. 630 27. Mahase E. 2019. Cystic fibrosis: Triple therapy shows promising results. The BMJ 631 367:6347. 632 Collins FS. 2019. Realizing the Dream of Molecularly Targeted Therapies for Cystic 28. 633 Fibrosis. New England Journal of Medicine 381:1862–1863. 634 Ooi CY, Syed SA, Rossi L, Garg M, Needham B, Avolio J, Young K, Surette MG, 29. 635 Gonska T. 2018. Impact of CFTR modulation with Ivacaftor on Gut Microbiota and 636 Intestinal Inflammation. Sci Rep 8:1–8. 637 30. Ronan NJ, Einarsson GG, Deane J, Fouhy F, Rea M, Hill C, Shanahan F. 2022. 638 Modulation, microbiota and inflammation in the adult CF gut : A prospective study. 639 Journal of Cystic Fibrosis https://doi.org/10.1016/j.jcf.2022.06.002. 640 31. Pope CE, Vo AT, Hayden HS, Weiss EJ, Durfey S, Mcnamara S, Ratjen A, Grogan B, 641 Carter S, Nay L, Parsek M, Singh P, McKone E, Aitken M, Rosenfeld M, Hoffman L. 642 2020. Changes in fecal microbiota with CFTR modulator therapy: A pilot study. Journal 643 of Cystic Fibrosis https://doi.org/10.1016/j.jcf.2020.12.002. 644 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. 2009. Research 32. 645 electronic data capture (REDCap)-A metadata-driven methodology and workflow process 646 for providing translational research informatics support. J Biomed Inform 42:377–381.

647	33.	Reasoner SA, Fazili IF, Bernard R, Parnell JM, Sokolow AG, Thomsen KF, Edwards KM,
648		Brown RF, Nicholson MR. 2022. Prevalence, Risk Factors, and Sequelae of
649		Asymptomatic Clostridioides difficile Colonization in Children with Cystic Fibrosis.
650		Journal of Cystic Fibrosis https://doi.org/10.1016/j.jcf.2022.12.014.
651	34.	Parnell JM, Fazili I, Bloch SC, Lacy DB, Garcia-Lopez VA, Bernard R, Skaar EP,
652		Edwards KM, Nicholson MR. 2021. Two-step Testing for Clostridioides Difficile is
653		Inadequate in Differentiating Infection From Colonization in Children. J Pediatr
654		Gastroenterol Nutr 72:378–383.
655	35.	Gaio D. Anantanawat K. To J. Liu M. Monahan L. Darling AE. 2022. Hackflex: Low-
656		cost, high-throughput, Illumina Nextera Flex library construction. Microb Genom 8.
657	36.	Aronesty E. 2011, ea-utils: Command-line tools for processing biological sequencing data.
658		https://github.com/ExpressionAnalysis/ea-utils.
659	37.	Blanco-Míguez A. Beghini F. Cumbo F. McIver I.J. Thompson KN. Zolfo M. Manghi P.
660	011	Dubois L. Huang KD. Thomas AM. Nickols WA. Piccinno G. Piperni E. Punčochář M.
661		Valles-Colomer M. Tett A. Giordano F. Davies R. Wolf J. Berry SE. Spector TD.
662		Franzosa EA. Pasolli E. Asnicar F. Huttenhower C. Segata N. 2023. Extending and
663		improving metagenomic taxonomic profiling with uncharacterized species using
664		MetaPhIAn 4 Nat Biotechnol https://doi.org/10.1038/s41587-023-01688-w
665	38	Dixon P 2003 VEGAN A Package of R Functions for Community Ecology Journal of
666	20.	Vegetation Science 14:927–930.
667	39.	Franzosa EA, McIver IJ, Rahnavard G, Thompson LR, Schirmer M, Weingart G, Lipson
668		KS. Knight R. Caporaso JG. Segata N. Huttenhower C. 2018. Species-level functional
669		profiling of metagenomes and metatranscriptomes. Nat Methods 15:962–968.
670	40.	Caspi R, Billington R, Keseler IM, Kothari A, Krummenacker M, Midford PE, Ong WK,
671		Paley S. Subhraveti P. Karp PD. 2020. The MetaCvc database of metabolic pathways and
672		enzymes-a 2019 update. Nucleic Acids Res 48:D455–D453.
673	41.	Abubucker S, Segata N, Goll J, Schubert AM, Izard J, Cantarel BL, Rodriguez-Mueller B,
674		Zucker J, Thiagarajan M, Henrissat B, White O, Kelley ST, Methé B, Schloss PD, Gevers
675		D, Mitreva M, Huttenhower C. 2012. Metabolic reconstruction for metagenomic data and
676		its application to the human microbiome. PLoS Comput Biol 8.
677	42.	Kaminski J, Gibson MK, Franzosa EA, Segata N, Dantas G, Huttenhower C. 2015. High-
678		Specificity Targeted Functional Profiling in Microbial Communities with ShortBRED.
679		PLoS Comput Biol 11.
680	43.	Jia B, Raphenya AR, Alcock B, Waglechner N, Guo P, Tsang KK, Lago BA, Dave BM,
681		Pereira S, Sharma AN, Doshi S, Courtot M, Lo R, Williams LE, Frye JG, Elsayegh T,
682		Sardar D, Westman EL, Pawlowski AC, Johnson TA, Brinkman FSL, Wright GD,
683		McArthur AG. 2017. CARD 2017: Expansion and model-centric curation of the
684		comprehensive antibiotic resistance database. Nucleic Acids Res 45:D566–D573.
685	44.	Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B,
686		Schwager E, Knights D, Song SJ, Yassour M, Morgan XC, Kostic AD, Luo C, González
687		A, McDonald D, Haberman Y, Walters T, Baker S, Rosh J, Stephens M, Heyman M,
688		Markowitz J, Baldassano R, Griffiths A, Sylvester F, Mack D, Kim S, Crandall W, Hyams
689		J, Huttenhower C, Knight R, Xavier RJ. 2014. The treatment-naive microbiome in new-
690		onset Crohn's disease. Cell Host Microbe 15:382–392.
691	45.	Enaud R, Hooks KB, Barre A, Barnetche T, Hubert C, Massot M, Bazin T, Clouzeau H,
692		Bui S, Fayon M, Berger P, Lehours P, Bébéar C, Nikolski M, Lamireau T, Delhaes L,

693		Schaeverbeke T. 2019. Intestinal Inflammation in Children with Cystic Fibrosis Is
694		Associated with Crohn's-Like Microbiota Disturbances. J Clin Med 8:645.
695	46.	Mallick H, Rahnavard A, McIver LJ, Ma S, Zhang Y, Nguyen LH, Tickle TL, Weingart
696		G, Ren B, Schwager EH, Chatterjee S, Thompson KN, Wilkinson JE, Subramanian A, Lu
697		Y, Waldron L, Paulson JN, Franzosa EA, Bravo HC, Huttenhower C. 2021. Multivariable
698		association discovery in population-scale meta-omics studies. PLoS Comput Biol 17.
699	47.	Salvers AA, Gupta A, Wang Y. 2004. Human intestinal bacteria as reservoirs for
700		antibiotic resistance genes. Trends Microbiol https://doi.org/10.1016/i.tim.2004.07.004.
701	48.	Wheatley RM, Caballero JD, van der Schalk TE, De Winter FHR, Shaw LP, Kapel N.
702		Recanatini C. Timbermont L. Kluvtmans J. Esser M. Lacoma A. Prat-Avmerich C. Oliver
703		A. Kumar-Singh S. Malhotra-Kumar S. Craig MacLean R. 2022. Gut to lung translocation
704		and antibiotic mediated selection shape the dynamics of Pseudomonas aeruginosa in an
705		ICU patient. Nat Commun 13:6523.
706	49	Rogers GB Carroll MP. Hoffman LR. Walker AW. Fine DA Bruce KD 2010
707		Comparing the microbiota of the cystic fibrosis lung and human gut. Gut Microbes 1.85–
708		93
709	50	Green HD Jones AM, 2022, Managing Pulmonary Infection in Adults With Cystic
710	001	Fibrosis: Adult Cystic Fibrosis Series, Chest, Elsevier Inc.
711		https://doi.org/10.1016/i.chest.2022.02.007.
712	51.	Beghini F. McIver I.J. Blanco-Míguez A. Dubois L. Asnicar F. Maharian S. Mailyan A.
713	011	Manghi P. Scholz M. Thomas AM. Valles-Colomer M. Weingart G. Zhang Y. Zolfo M.
714		Huttenhower C. Franzosa EA. Segata N. 2021. Integrating taxonomic functional and
715		strain-level profiling of diverse microbial communities with biobakery 3. Elife 10.
716	52.	Mall MA, Brugha R, Gartner S, Legg J, Moeller A, Mondeiar-Lopez P, Prais D, Pressler
717	0	T. Ratien F. Reix P. Robinson PD. Selvadurai H. Stehling F. Ahluwalia N. Arteaga-Solis
718		E. Bruinsma BG. Jennings M. Moskowitz SM. Noel S. Tian S. Weinstock TG. Wu P.
719		Wainwright CE, Davies JC, 2022, Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor
720		in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del
721		and a Minimal Function Mutation A Phase 3b Randomized. Placebo-controlled Study.
722		Am I Respir Crit Care Med 206:1361–1369
723	53	Streibel C. Willers CC. Pusterla O. Bauman G. Stranzinger E. Brabandt B. Bieri O. Curdy
724	00.	M. Bullo M. Frauchiger BS. Korten I. Krüger L. Casaulta C. Ratien F. Latzin P. Kieninger
725		E. 2023. Effects of elexacattor/tezacattor/ivacattor therapy in children with cystic fibrosis
726		- a comprehensive assessment using lung clearance index spirometry and functional and
727		structural lung MRL Journal of Cystic Fibrosis https://doi.org/10.1016/j.jcf.2022.12.012
728	54	Iordan KD Zemanick ET Taylor-Cousar II. Hoppe IE 2023 Managing cystic fibrosis in
729	51.	children aged 6-11 vrs: a critical review of elevacattor/tezacattor/ivacattor combination
730		therapy Expert Rev Respir Med Taylor and Francis I td
731		https://doi.org/10.1080/17476348.2023.2179989
732	55	Kapouni N Moustaki M Douros K Loukou L 2023 Efficacy and Safety of Elevacator-
732	55.	Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review Children
734		10.554
735	56	Wainwright C McColley SA McNally P Powers M Ratien F Rayment IH Retsch
736	50.	Bogart G Roesch F Ahluwalia N Chin A Chu C Lu M Menon P Waltz D Weinstock
737		T Zelazoski I Davies IC VX19-445-107 Study Group 2023 Long-Term Safety and
738		Efficacy of Elevacator/Teracator/Jyacator in Children Aged >6 Vers with Cyclic
130		Entracy of Elexaction relation in condition $\operatorname{Aged} \ge 0$ reals with Cystic

720		Ethersis and At Least One E500 dat Allalas A Diseas 2. Onen Label Clinical Trial And L
/39		Fibrosis and At Least One F508del Allele: A Phase 3, Open-Label Clinical Irial. Am J
740		Respir Crit Care Med https://doi.org/10.1164/rccm.202301-0021OC.
741	57.	Cornet M, Robin G, Ciciriello F, Bihouee T, Marguet C, Roy V, Lebourgeois M,
742		Chedevergne F, Bonnel AS, Kelly M, Reix P, Lucidi V, Stoven V, Sermet-Gaudelus I.
743		2022. Profiling the response to lumacaftor-ivacaftor in children with cystic between
744		fibrosis and new insight from a French-Italian real-life cohort. Pediatr Pulmonol
745		https://doi.org/10.1002/ppul.26123.
746	58.	Appelt D, Steinkamp G, Sieber S, Ellemunter H. 2023. Early and sustained improvements
747		of lung clearance index from two to sixteen weeks of elexacaftor/tezacaftor/ivacaftor
748		therapy in patients with cystic fibrosis—a real world study. Front Pharmacol 14.
749	59.	Gramegna A, Majo F, Alicandro G, Leonardi G, Cristiani L, Amati F, Contarini M,
750		Aliberti S. Fiocchi AG, Blasi F. 2023. Heterogeneity of weight gain after initiation of
751		Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis. Respir Res 24.
752	60	Matamouros S Hayden HS Hager KR Brittnacher MI Lachance K Weiss EL Pone CE
753	00.	Imbaus AF McNally CP Borenstein F Hoffman I R Miller SI 2018 Adaptation of
754		commensal proliferating Escherichia coli to the intestinal tract of young children with
755		evotia fibrosia. Prog Natl Acad Sci U.S. A 115:1605, 1610
755	61	Eraitas MB De Addison E Moraira M Tomio C Maria V Morano E Daltos EP Barbosa
750	01.	E Noto NL Buggigrossi V Guarino A 2018 Altered intestinal microbiota composition
750		E, Neto NE, Buccigrossi V, Ouanno A. 2018. Altered intestinal interoblota composition,
750		fibrosis. DLoS One 12
739	(\mathbf{c})	IDIOSIS, PLOS OIIE 15. Duutashaavan C. Huwa C. Dakaart M. Daulan aan L. Da Daaala K. Mandamma D. 2012
/60	62.	Duytschaever G, Huys G, Bekaert M, Boulanger L, De Boeck K, Vandamme P. 2013.
/61		Dysbiosis of bifidobacteria and Clostridium cluster XIVa in the cystic fibrosis fecal
762	60	microbiota. Journal of Cystic Fibrosis 12:206–215.
763	63.	Nielsen S, Needham B, Leach ST, Day AS, Jaffe A, Thomas T, Ooi CY. 2016. Disrupted
764		progression of the intestinal microbiota with age in children with cystic fibrosis. Sci Rep
765		6.
766	64.	Debyser G, Mesuere B, Clement L, Van de Weygaert J, Van Hecke P, Duytschaever G,
767		Aerts M, Dawyndt P, De Boeck K, Vandamme P, Devreese B. 2016. Faecal proteomics: A
768		tool to investigate dysbiosis and inflammation in patients with cystic fibrosis. Journal of
769		Cystic Fibrosis 15:242–250.
770	65.	Bernard R, Shilts MH, Strickland BA, Boone HH, Payne DC, Brown RF, Edwards K, Das
771		SR, Nicholson MR. 2023. The relationship between the intestinal microbiome and body
772		mass index in children with cystic fibrosis. Journal of Cystic Fibrosis
773		https://doi.org/10.1016/j.jcf.2023.11.002.
774	66.	Hollister EB, Riehle K, Luna RA, Weidler EM, Rubio-Gonzales M, Mistretta TA, Raza S,
775		Doddapaneni H V., Metcalf GA, Muzny DM, Gibbs RA, Petrosino JF, Shulman RJ,
776		Versalovic J. 2015. Structure and function of the healthy pre-adolescent pediatric gut
777		microbiome. Microbiome 3:36.
778	67.	Mehta RS, Abu-Ali GS, Drew DA, Lloyd-Price J, Subramanian A, Lochhead P, Joshi AD,
779		Ivey KL, Khalili H, Brown GT, Dulong C, Song M, Nguyen LH, Mallick H, Rimm EB,
780		Izard J. Huttenhower C. Chan AT. 2018. Stability of the human faecal microbiome in a
781		cohort of adult men. Nat Microbiol 3:347–355.
782	68	David LA. Materna AC. Friedman J. Campos-Baptista MI. Blackburn MC. Perrotta A
783	00.	Erdman SE Alm EI 2014 Host lifestyle affects human microbiota on daily timescales
784		Genome Biol 15
104		

785 69. Faith JJ, Guruge JL, Charbonneau M, Subramanian S, Seedorf H, Goodman AL, Clemente 786 JC, Knight R, Heath AC, Leibel RL, Rosenbaum M, Gordon JI. 2013. The long-term 787 stability of the human gut microbiota. Science (1979) 341. 788 70. Yamada A, Komaki Y, Komaki F, Micic D, Zullow S, Sakuraba A. 2018. Risk of 789 gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-790 analysis. Lancet Oncol 19:758-767. 791 71. Garg M, Leach ST, Coffey MJ, Katz T, Strachan R, Pang T, Needham B, Lui K, Ali F, 792 Day AS, Appleton L, Moeeni V, Jaffe A, Ooi CY. 2017. Age-dependent variation of fecal 793 calprotectin in cystic fibrosis and healthy children. Journal of Cystic Fibrosis 16:631-636. 794 72. Rumman N, Sultan M, El-Chammas K, Goh V, Salzman N, Quintero D, Werlin S. 2014. 795 Calprotectin in Cystic Fibrosis. BMC Pediatr 14. 796 73. Beaufils F, Mas E, Mittaine M, Addra M, Fayon M, Delhaes L, Clouzeau H, Galode F, 797 Lamireau T, Bui S, Enaud R. 2020. Increased Fecal Calprotectin Is Associated with 798 Worse Gastrointestinal Symptoms and Quality of Life Scores in Children with Cystic 799 Fibrosis. J Clin Med 9:4080. 800 74. Schwarzenberg SJ, Vu PT, Skalland M, Hoffman LR, Pope C, Gelfond D, Narkewicz MR, 801 Nichols DP, Heltshe SL, Donaldson SH, Frederick CA, Kelly A, Pittman JE, Ratjen F, 802 Rosenfeld M, Sagel SD, Solomon GM, Stalvey MS, Clancy JP, Rowe SM, Freedman SD. 803 2022. Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: 804 Report of promise-GI. Journal of Cystic Fibrosis https://doi.org/10.1016/j.jcf.2022.10.003. 805 Mainz JG, Lester K, Elnazir B, Williamson M, McKone E, Cox D, Linnane B, Zagoya C, 75. 806 Duckstein F, Barucha A, Davies JC, McNally P. 2023. Reduction in abdominal symptoms 807 (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment 808 with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥ 12 years – The 809 RECOVER study. Journal of Cystic Fibrosis https://doi.org/10.1016/j.jcf.2023.10.001. 810 76. Baldwin-Hunter BL, Rozenberg FD, Annavajhala MK, Park H, DiMango EA, Keating 811 CL, Uhlemann A-C, Abrams JA. 2023. The gut microbiome, short chain fatty acids, and 812 related metabolites in cystic fibrosis patients with and without colonic adenomas. Journal 813 of Cystic Fibrosis https://doi.org/10.1016/j.jcf.2023.01.013. 814 Miragoli F, Federici S, Ferrari S, Minuti A, Rebecchi A, Bruzzese E, Buccigrossi V, 77. Guarino A, Callegari ML. 2017. Impact of cystic fibrosis disease on archaea and bacteria 815 816 composition of gut microbiota. FEMS Microbiol Ecol 93. 817 Burke DG, Fouhy F, Harrison MJ, Rea MC, Cotter PD, O'Sullivan O, Stanton C, Hill C, 78. 818 Shanahan F, Plant BJ, Ross RP. 2017. The altered gut microbiota in adults with cystic 819 fibrosis. BMC Microbiol 17:1-11. 820 79. Rivera-Chávez F, Lopez CA, Bäumler AJ. 2017. Oxygen as a driver of gut dysbiosis. Free 821 Radic Biol Med. Elsevier Inc. https://doi.org/10.1016/j.freeradbiomed.2016.09.022. 822 80. Shah YM. 2016. The role of hypoxia in intestinal inflammation. Mol Cell Pediatr 3. 823 81. Rigottier-Gois L. 2013. Dysbiosis in inflammatory bowel diseases: The oxygen 824 hypothesis. ISME Journal https://doi.org/10.1038/ismej.2013.80. 825 82. López-Causapé C, Rojo-Molinero E, MacIà MD, Oliver A. 2015. The problems of 826 antibiotic resistance in cystic fibrosis and solutions. Expert Rev Respir Med. Expert 827 Reviews Ltd. https://doi.org/10.1586/17476348.2015.995640. 828 83. Taylor SL, Leong LEX, Sims SK, Keating RL, Papanicolas LE, Richard A, Mobegi FM, 829 Wesselingh S, Burr LD, Rogers GB. 2021. The cystic fibrosis gut as a potential source of 830 multidrug resistant pathogens. Journal of Cystic Fibrosis 20:413-420.

It is made available under a CC-BY-ND 4.0 International license .

- 831 84. Fredriksen S, de Warle S, van Baarlen P, Boekhorst J, Wells JM. 2023. Resistome 832 expansion in disease-associated human gut microbiomes. Microbiome 11:166.
- 833 85. Patel D, Mathews S, van Unen V, Chan JE, Al-Hammadi N, Borowitz D, Gelfond D,
 834 Sellers ZM. 2022. Impaired distal colonic pH in adults with cystic fibrosis. Journal of
 835 Cystic Fibrosis https://doi.org/10.1016/j.jcf.2022.12.011.
- 836 86. Gelfond D, Heltshe S, Ma C, Rowe SM, Frederick C, Uluer A, Sicilian L, Konstan M,
 837 Tullis E, Roach RNC, Griffin K, Joseloff E, Borowitz D. 2017. Impact of CFTR
 838 modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis
 839 and the G551D mutation. Clin Transl Gastroenterol 8.
- 840

841 **TABLES AND FIGURES**

- 842 Table 1. Cohort Baseline Details
- 843 Figure 1. Study Schematic, Timeline, and Clinical Improvement after ELX/TEZ/IVA
- 844 Figure 2. Microbiome Diversity Increases After ELX/TEZ/IVA
- 845 Figure 3. Intestinal Carriage of Antibiotic Resistance Genes
- 846 Figure 4. Specific Microbial Taxonomic Changes after ELX/TEZ/IVA
- 847 Figure 5. Intestinal Inflammation Decreases after ELX/TEZ/IVA and Microbiome
- 848 Functional Changes
- 849 Supplementary Figure 1. Clinical Data Across the Four-Timepoints
- 850 Supplementary Figure 2. Microbiome Alpha Diversity and Beta Diversity
- 851 Supplementary Figure 3. Prior CFTR Modulators and Microbiome Diversity
- 852 Supplementary Figure 4. Reduced Abundance of Intestinal Antibiotic Resistance Genes
- 853 Supplementary Figure 5. Respiratory Taxa in Stool Samples
- 854 Supplementary Figure 6. Fecal Calprotectin at Four-Timepoints and Differentially
- 855 Abundant KEGG Orthology Groups
- 856 Supplementary Figure 7. Differentially Abundant MetaCyc Pathways
- 857 Supplementary Table S1. Complete Metadata
- 858 Supplementary Table S2. Species MaAsLin2 Results
- 859 Supplementary Table S3. Differentially Abundant Species with Respect to ELX/TEZ/IVA
- 860 Supplementary Table S4. MaAsLin2 Results Across Taxonomic Levels
- 861 Supplementary Table S5. MaAsLin2 Results of Antibiotic Resistance Genes
- 862 Supplementary Table S6. MaAsLin2 Results of KEGG Orthology Groups
- 863 Supplementary Table S7. Differentially Abundant KEGG Orthology Groups with Respect
- 864 to ELX/TEZ/IVA
- 865 Supplementary Table S8. MaAsLin2 Results of MetaCyc Pathways
- 866 Supplementary Table S9. Differentially Abundant MetaCyc Pathways with Respect to
- 867 ELX/TEZ/IVA

It is made available under a CC-BY-ND 4.0 International license .

868 Supplementary Table S10. Stratified Taxonomic Output of Differentially Abundant KEGG

- 869 **Orthology Groups**
- 870 Supplementary Dataset 1. Compiled Metadata and Metagenomic Results
- 871

872 **FIGURE LEGENDS**

873

Figure 1. Study Schematic, Timeline, and Clinical Improvement after ELX/TEZ/IVA.

A) Overview of study procedure and analyses. B) Timeline illustrating the four timepoints. Day 0

- is depicted as the day of ELX/TEZ/IVA initiation. A total of 114 samples were collected from 39
- unique patients, of which 53 samples were before ELX/TEZ/IVA treatment and 61 samples after
- treatment. C-E) Depictions of clinical data before and after ELX/TEZ/IVA; (C) ppFEV1, (D) BMI
- percentile, (E) antibiotic days per 6-months. Each dot represents the clinical data associated
- 880 with a stool sample. P values calculated by Wilcoxon rank-sum test.
- 881

882 Figure 2. Microbiome Diversity and Intestinal Carriage of Antibiotic Resistance Genes.

- 883 A) Phylum level relative abundance for samples collected before (samples=53) and after
- 884 (samples=61) ELX/TEZ/IVA. Samples are organized by the relative abundance of the phylum
- 885 Firmicutes. **B-C)** Alpha diversity before and after ELX/TEZ/IVA. Shannon Index calculated with
- the R package vegan using species abundance table from Metaphlan4. Microbial richness
- represents the number of unique species per sample. Each dot represents a stool sample
- 888 (samples=114). P values calculated by Wilcoxon rank-sum test. **D-E)** Alpha diversity between
- samples with and without recent antibiotic exposure. Recent antibiotic exposure categorized as
- any systemic antibiotic within the past 6-months. Shannon Index calculated with the R package
- 891 vegan using species abundance table from MetaPhIAn4. Microbial richness represents the
- number of unique species per sample. Each dot represents a stool sample (samples=114). P
- 893 values calculated by Wilcoxon rank-sum test.
- 894
- Figure 3. A) Antibiotic resistance gene (ARG) abundance (RPKM) before and after
- 896 ELX/TEZ/IVA. ARGs were profiled using ShortBRED and the Comprehensive Antibiotic
- 897 Resistance Database (CARD). Each dot represents a stool sample (samples=114). P values
- calculated by Wilcoxon rank-sum test. **B)** ARG abundance (RPKM) by class of antibiotic to
- 899 which they confer resistance. Abundance values of zero are plotted on the vertical axis. P
- 900 values calculated by Wilcoxon signed-rank test.
- 901

It is made available under a CC-BY-ND 4.0 International license .

902 Figure 4. Specific Microbial Taxonomic Changes after ELX/TEZ/IVA.

- 903 A) Differentially abundant species before and after ELX/TEZ/IVA. The results are depicted with 904 significance (-log10 of the FDR) (Y axis) vs. log2(FoldChange). MaAsLin2 multivariable 905 association modeling was implemented in R, using ELX/TEZ/IVA status, age, and recent 906 antibiotics as fixed effects in the model. Participant ID was used as a random effect. Horizontal 907 dashed line depicts FDR=0.1. Species reaching statistical significance (FDR≤0.10) are 908 highlighted in solid colors whereas other species are gray. B) Species of interest from 909 differential abundance testing before and after ELX/TEZ/IVA. Vertical axis is log10 transformed. 910 MaAsLin2 FDR is depicted. Zero values are plotted on the horizontal axes. The percentage of
- 911 samples for which the relative abundance was zero is depicted below the graph.
- 912

913 Figure 5. Intestinal Inflammation Decreases after ELX/TEZ/IVA and Microbiome

914 Functional Changes. A) Fecal calprotectin before and after ELX/TEZ/IVA. Each dot represents

- 915 a stool sample (samples=114). P values calculated by Wilcoxon rank-sum test. **B-C)** Microbial
- 916 dysbiosis index (MD-INDEX) before and after ELX/TEZ/IVA (B) or between samples with and
- 917 without recent antibiotic exposure (C). MD-index calculated as the log10 ratio of species
- 918 positively/negatively correlated with new onset pediatric Crohn's disease (44). Each dot
- 919 represents a stool sample (samples=114). P values calculated by Wilcoxon rank-sum test. **D**)
- 920 Differentially abundant KEGG orthologs following MaAsLin2 multivariable association modeling,
- 921 using ELX/TEZ/IVA status, age, and recent antibiotics as fixed effects in the model. Participant
- 922 ID was used as a random effect. Horizontal dashed line depicts FDR=0.25. E) Subset of
- 923 differentially abundant MetaCyc pathways following MaAsLin2 multivariable association
- 924 modeling, using ELX/TEZ/IVA status, age, and recent antibiotics as fixed effects in the model.
- 925 Only pathways with FDR<0.25 are depicted.
- 926

927 Supplementary Figure S1. A-D) Clinical metadata vs. timepoint; (A) ppFEV1, (B) BMI

percentile, (C) weight percentile, and (D) height percentile. Each dot represents the clinical data
associated with a stool sample. Red line indicates the mean, and gray lines represent individual
patients. P values calculated by Wilcoxon signed-rank test.

931

932 Supplementary Figure S2. A-B) Alpha diversity vs. timepoint. Shannon Index (A) calculated
 933 with the R package vegan using species abundance table from Metaphlan4. Microbial richness

with the republicage vegan doing opeolee abandance table norm metaphian it moreblar hormore

- 934 (**B**) represents the number of unique species per sample. Each dot represents a stool sample
- 935 (samples=114). P values calculated by Wilcoxon signed-rank test. **C)** Principal component

It is made available under a CC-BY-ND 4.0 International license .

936 analysis of Bray-Curtis distances before and after ELX/TEZ/IVA. Bray-Curtis distance matrix 937 computed with vegan. PERMANOVA and PERMDISP computed by the vegan package with the 938 functions adonis2 and betadisp, respectively. Ellipse depicts the 95% confidence level. D) 939 Principal component analysis of weighted UniFrac distances before and after ELX/TEZ/IVA. 940 Weighted UniFrac computed with MetaPhIAn4 R script. PERMANOVA and PERMDISP 941 computed by the vegan package with the functions adonis2 and betadisp, respectively. Ellipse 942 depicts the 95% confidence level. E) Principal component analysis of the Bray-Curtis distances 943 between samples with and without recent antibiotic exposure. Distance matrix generated by the 944 R package vegan using the MetaPhIAn4 species table. PERMANOVA and PERMDISP 945 computed in vegan with the functions adonis2 and betadisp, respectively. Ellipse depicts the 946 95% confidence level.

947

948 Supplementary Figure S3. A-B) Diversity metrics of pre-ELX/TEZ/IVA samples (samples=53) 949 total). Samples are grouped by whether the subject was receiving another CFTR modulator at 950 the time of sample collection (Yes=8, No=45). C-D) Diversity metrics of pre-ELX/TEZ/IVA 951 samples (samples=53) compared to post-ELX/TEZ/IVA samples (samples=61). Post-952 ELX/TEZ/IVA samples were segregated by whether the subject had previously received any 953 other CFTR modulator (Yes=20 samples, No=41 samples). Shannon Index calculated with the 954 R package vegan using species abundance table from MetaPhIAn4. Microbial richness 955 represents the number of unique species per sample. P values calculated by Wilcoxon rank-

- 956 sum test.
- 957

958 Supplementary Figure S4. A) Cumulative antibiotic days per 6-months prior to stool sample 959 collection. P values calculated by Wilcoxon signed-rank test. B) ARG richness (unique genes) 960 before and after ELX/TEZ/IVA. ARGs were profiled using ShortBRED and the Comprehensive 961 Antibiotic Resistance Database (CARD). Each dot represents a stool sample (samples=114). P 962 values calculated by Wilcoxon rank-sum test. C) Cumulative relative abundance (RPKM) of 963 ARGs conferring resistance to peptide antibiotics. P values calculated by Wilcoxon rank-sum 964 test. D) Relative abundance (RPKM) of the most prevalent ARGs conferring resistance to 965 peptide antibiotics. MaAsLin2 FDR is depicted. E) Cumulative relative abundance (RPKM) of 966 ARGs conferring resistance to other antibiotics. P values calculated by Wilcoxon rank-sum test. 967 F) Relative abundance (RPKM) of the most prevalent ARGs conferring resistance to other 968 antibiotics. MaAsLin2 FDR is depicted.

969

It is made available under a CC-BY-ND 4.0 International license .

970 Supplementary Figure S5. A) Roseburia faecis relative abundance between samples with and 971 without recent antibiotic exposure. Each dot represents a stool sample (samples=114). 972 MaAsLin2 FDR is depicted. B) Relative abundance of respiratory genera in stool samples 973 before and after ELX/TEZ/IVA. Each dot represents a stool sample (samples=114). MaAsLin2 974 FDR is depicted. Vertical axis is log10 transformed. Zero values are plotted on the horizontal 975 axes. 976 977 **Supplementary Figure S6. A)** Fecal calprotectin ($\mu q/q$) vs. study timepoint. Red line indicates 978 the mean, and gray lines represent individual patients. P values calculated by Wilcoxon signed-979 rank test. B) Differentially abundant oxidative phosphorylation KEGG orthology (KO) groups 980 from MaAsLin2 (FDR<0.25). Groups correspond to red points in Fig. 5A. log2(FoldChange), 981 which is equivalent to MaAsLin2 coefficient, is depicted. C) Taxonomic stratification of 982 differentially abundant oxidative phosphorylation KO groups. KO groups correspond to groups in 983 panel A. 984 985 Supplementary Figure S7. Differentially abundant MetaCyc pathways following MaAsLin2 986 multivariable association modeling, using ELX/TEZ/IVA status, age, and recent antibiotics as

987 fixed effects in the model. Only pathways with FDR<0.25 are depicted.





Shannon Index (microbial species)







medRxiv preprint doi: https://doi.org/10.1101/2023.08.11.23293949; this version posted November 21, 2023. The copyright holder for this



Supplementation of the state of

It is made available under a CC-BY-ND 4.0 International license .



medRxiv preprint doi: https://doi.org/10.1101/2023.08.11.23293949; this version posted November 21, 2023. The copyright holder for this Supplementation of the second seco

It is made available under a CC-BY-ND 4.0 International license .

Before ELX/TEZ/IVA

53 total samples 45 modulator naïve samples 8 samples on another modulator

After ELX/TEZ/IVA

61 total samples

41 samples from subjects without prior modulator use 20 samples from subjects with prior modulator use





20



Supplemental Figure or 410.1101/2023.08.11.23293949; this version posted November 21, 2023. The copyright holder for this supplementation of the supplementation



Supplementation of the state of

It is made available under a CC-BY-ND 4.0 International license .



Supplementation of the state of

It is made available under a CC-BY-ND 4.0 International license . 0.1513 $\,$





It is made available under a CC-BY-ND 4.0 International license . $MetaCyc \ Pathway$

